Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Cash from Operations (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Cash from Operations data on record, last reported at 63945000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 96.9% year-over-year to 63945000.0; the TTM value through Dec 2025 reached 210945000.0, down 33.7%, while the annual FY2025 figure was 210945000.0, 33.7% down from the prior year.
  • Cash from Operations reached 63945000.0 in Q4 2025 per CLDX's latest filing, down from 48600000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 11930000.0 in Q2 2021 and bottomed at 63945000.0 in Q4 2025.
  • Average Cash from Operations over 5 years is 32032750.0, with a median of 28948000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: soared 46.03% in 2023, then crashed 191.35% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 14523000.0 in 2021, then tumbled by 49.85% to 21762000.0 in 2022, then tumbled by 49.49% to 32533000.0 in 2023, then rose by 0.18% to 32476000.0 in 2024, then tumbled by 96.9% to 63945000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 63945000.0 in Q4 2025, 48600000.0 in Q3 2025, and 44028000.0 in Q2 2025.